Abstract: The use of monoclonal antibodies for treating ovarian cancer has been gaining interest and has already made impressive progress in both the pre-clinical and clinical trials. Bevacizumab inhibits tumor growth through anti-angiogenesis Trastuzumab and pertuzumab inhibit tumor growth after binding with HER2. Cetuximab enhances cell apoptosis and interferes with cancer cell proliferation after binding with EGFR1. Oregovomab binds to CA125, forming complexes that cause a specific immune response to CA125. Targeted treatment with monoclonal antibodies can make up for the deficiency of traditional treatment. This paper reviews the recent achievements in the development of monoclonal antibodies for treating ovarian cancer.

Key words: Ovarian cancer, Monoclonal antibodies, Treatment